Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H24N6O10S2.Na.H |
Molecular Weight | 692.652 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Na+].[H][C@]12SCC(C[N+]3=CC=C(CCS([O-])(=O)=O)C=C3)=C(N1C(=O)[C@H]2NC(=O)[C@@H](NC(=O)C4=C(NC=N4)C([O-])=O)C5=CC=CC=C5)C([O-])=O
InChI
InChIKey=JLUNZNNMKVKUOH-TZVBBFNXSA-M
InChI=1S/C28H26N6O10S2.Na/c35-23(18(16-4-2-1-3-5-16)31-24(36)19-20(27(38)39)30-14-29-19)32-21-25(37)34-22(28(40)41)17(13-45-26(21)34)12-33-9-6-15(7-10-33)8-11-46(42,43)44;/h1-7,9-10,14,18,21,26H,8,11-13H2,(H5-,29,30,31,32,35,36,38,39,40,41,42,43,44);/q;+1/p-1/t18-,21+,26+;/m0./s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C28H24N6O10S2 |
Molecular Weight | 668.654 |
Charge | -2 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6605719Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/3041630, http://www.ncbi.nlm.nih.gov/pubmed/4032736
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6605719
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/3041630, http://www.ncbi.nlm.nih.gov/pubmed/4032736
Cefpimizole is an antibiotic of broad spectrum developed in Japan for the treatment of such conditions as uncomplicated gonorrhea and gynecologic infections. The drug was tested in clinical trials, however, its development was terminated.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of AC-1370, a new semisynthetic cephalosporin, on phagocyte functions. | 1983 Jun |
|
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin. | 1983 Sep |
|
Mechanism of action of AC-1370 on phagocyte functions. | 1984 Jan |
|
Clinical study of cefpimizole in obstetric and gynecologic infections. | 1985 Apr |
|
High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. | 1987 Dec |
|
Comparison of cefpimizole with cefotaxime and penicillin G for treatment of uncomplicated gonorrhea. | 1988 Apr-Jun |
|
Upregulatory effects of cefpimizole natrium on human leukocytes. | 1992 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3041630
1.0 g of cefpimizole (gonorrea treatment).
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6605719
In vitro activity of cefpimizole was tested against C. diversus (MIC 0.4-12.5 ug/ml), H. influenzae (MIC 0.1-0.4 ug/ml), N. gonorrhoeae (MIC 0.1-1.6 ug/ml), Proteus mirabilis (MIC 0.2-12.5 ug/ml), Streptococcus pyogenes (MIC 0.4-3.1 ug/ml), Streptococcus bovis (MIC 1.6-3.1 ug/ml), Streptococcus mitis (MIC 0.2-3.1 ug/ml), Streptococcus agalactiae (MIC 0.8-3.1 ug/ml).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:45 GMT 2023
by
admin
on
Fri Dec 15 15:17:45 GMT 2023
|
Record UNII |
X4628IMC52
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2103902
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
85287-61-2
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
SUB01129MIG
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
100000084700
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
W-118
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
m1060
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
C81031
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
55324
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
DTXSID401005778
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY | |||
|
X4628IMC52
Created by
admin on Fri Dec 15 15:17:45 GMT 2023 , Edited by admin on Fri Dec 15 15:17:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |